Cassava Sciences, Inc. (SAVA)
- Previous Close
21.19 - Open
21.01 - Bid 19.51 x 1300
- Ask 19.76 x 1100
- Day's Range
19.47 - 21.19 - 52 Week Range
12.32 - 32.10 - Volume
1,184,730 - Avg. Volume
722,185 - Market Cap (intraday)
849.131M - Beta (5Y Monthly) -0.40
- PE Ratio (TTM)
-- - EPS (TTM)
-2.32 - Earnings Date Apr 29, 2024 - May 3, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Dec 13, 2012
- 1y Target Est
--
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
www.cassavasciences.comRecent News: SAVA
Performance Overview: SAVA
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SAVA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SAVA
Valuation Measures
Market Cap
915.95M
Enterprise Value
794.81M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
6.66
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-7.61
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-34.27%
Return on Equity (ttm)
-53.27%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-97.22M
Diluted EPS (ttm)
-2.32
Balance Sheet and Cash Flow
Total Cash (mrq)
121.14M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-51.57M
Research Analysis: SAVA
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell